Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.76. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VCIT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $84.82 |
52-Week Low | $4.17 | $81.54 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VCIT trades at $82.39 with minimal daily movement (+0.06%) amid bearish technical signals from moving averages. The ETF maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective intermediate-term corporate bond option. Recent dividend distributions of $0.33-$0.34 highlight consistent income generation, though technical indicators show 14 sell signals against 2 buy signals.
Outlook remains cautious due to bearish technical momentum and corporate bond market sensitivity to interest rate changes. The fund's low-cost structure and steady yield appeal to income-focused investors, but potential volatility from Federal Reserve policy shifts presents near-term risk. Current levels near support at $82 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
